Association Between Genetic Variant Scores and Warfarin Effect
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Atrial Fibrillation
- Deep Vein Thrombosis
- Intracardiac Thrombus
- Pulmonary Embolism
- Venous Thromboembolic Disease
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 99 years
- Gender
- Both males and females
Description
It is anticipated that next generation genomic sequencing will identify rare genetic variants in ethnically diverse populations, which otherwise would not have been detected using commercially available warfarin tests. Furthermore, retrospective review of clinical outcomes (percent time in therapeut...
It is anticipated that next generation genomic sequencing will identify rare genetic variants in ethnically diverse populations, which otherwise would not have been detected using commercially available warfarin tests. Furthermore, retrospective review of clinical outcomes (percent time in therapeutic range, time to reach therapeutic international normalized ratio (INR), INR ? 4, major bleeding event, ischemic stroke) of study participants will determine the clinical utility of genetic variant risk scores. Study outcomes will provide guidance on future directions for optimizing dosing algorithms for warfarin that combine pharmacogenetic principles with clinical dosing.
Tracking Information
- NCT #
- NCT03894878
- Collaborators
- Santa Clara Valley Medical Center
- Investigators
- Principal Investigator: Clifford Wang, MD Santa Clara Valley Medical Center Study Director: Jessica Song, PharmD Santa Clara Valley Medical Center Study Director: Michelle Wilson, MD Santa Clara Valley Medical Center
Get Well Soon